echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Ann Oncol: The efficacy of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed anti-PD-1

    Ann Oncol: The efficacy of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed anti-PD-1

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Regulation of DNA damage response and repair (DDR) pathways is a promising strategy for tumor immunotherapy
    .


    Ceralasertib (AZD6738) is an oral inhibitor of serine/threonine protein kinase and Rad3-related protein, which is essential for DDR


    Regulation of DNA damage response and repair (DDR) pathways is a promising strategy for tumor immunotherapy


    Of the 30 patients included in the study, 29 were assessed for response, with a median follow-up of 14.
    5 months
    .


    Nine patients (30.


    Of the 30 patients included in the study, 29 were assessed for response, with a median follow-up of 14.


    Median progression-free survival (PFS) was 7.
    1 months (95% CI, 3.
    6-10.
    6 months) and median OS was 14.
    2 months (95% CI, 9.
    3-19.
    1 months)
    .


    Exploratory analyses revealed no significant differences in survival among subgroups stratified by clinicopathological features


    Median progression-free survival (PFS) was 7.


    Treatment-emergent adverse events (AEs) of different grades occurred in 29 (96.
    7%) patients
    .


    More than half of the patients had anemia (76.


    Treatment-emergent adverse events (AEs) of different grades occurred in 29 (96.


    Exploratory biomarker analysis showed that tumors with immune-enhancing microenvironments or altered DDR pathways were more likely to respond to the study treatment
    .

    Exploratory biomarker analysis showed that tumors with immune-enhancing microenvironments or altered DDR pathways were more likely to respond to the study treatment
    .


    Exploratory biomarker analysis showed that tumors with immune-enhancing microenvironments or altered DDR pathways were more likely to respond to the study treatment


    Taken together, the study shows that ceralasertib (AZD6738) combined with the PD-L1 inhibitor durvalumab is a promising treatment option
    .

    Taken together, the study shows that ceralasertib (AZD6738) combined with the PD-L1 inhibitor durvalumab is a promising treatment option
    .


    Studies have shown that ceralasertib (AZD6738) in combination with the PD-L1 inhibitor durvalumab is a promising treatment option


    Original source:

    Kim R, Kwon M, An M, Kim ST, Smith SA, Loembé AB, Mortimer PGS, Armenia J, Lukashchuk N, Shah N, Dean E, Park WY, Lee J.
    Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
    Ann Oncol.
    2022 Feb;33(2):193-203.
    doi: 10.
    1016/j.
    annonc.
    2021.
    10.
    009.
    Epub 2021 Oct 25 .
    PMID: 34710570.

    Kim R, Kwon M, An M, Kim ST, Smith SA, Loembé AB, Mortimer PGS, Armenia J, Lukashchuk N, Shah N, Dean E, Park WY, Lee J.
    Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
    Ann Oncol.
    2022 Feb;33(2):193-203.
    doi: 10.
    1016/j.
    annonc.
    2021.
    10.
    009.
    Epub 2021 Oct 25 .
    PMID: 34710570.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.